N. Methodological Consideration for Clinical Development of Bevacizumab Biosimilar Candidate,
Rep Radiother Oncol.
Online ahead of Print
; In Press(In Press):e91577.
U.S. Department of Health and Human Services; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating bio similarity to a reference product. Guidance for industry. Food and Drug Administration; 2015.
European Medicines Agency Evaluation of Medicines for Human Use. Guideline on similar biological medicinal products. London: Committee for Medicinal Products for Human Use (CHMP); 2005.
He K, Chen H, Gwise T, Casak S, Lemery S, Keegan P, et al. Statistical considerations in evaluating a biosimilar product in an oncology clinical study. Clin Cancer Res. 2016;22(21):5167-70. doi: 10.1158/1078-0432.CCR-16-1010. [PubMed: 27582485].
Heinzmann D. Methodological considerations for clinical equivalence of bevacizumab biosimilars. Ann Oncol. 2016;27. doi: 10.1093/annonc/mdw603.016.
World Health Organization. Expert committee on biological standardization. Guidelines on evaluation of similar bio therapeutic products (SBPs). World Health Organization; 2009.
Eropean Medicine Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. Committee for Medicinal Products for Human Use (CHMP); 2014.
PBRER. Roche data on file. Safety Report; 2017.